Authors reply: an adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples

Giuseppe Di LorenzoUniversity Federico II of Napoli, Department of Medical Oncology, Endocrinology and Oncology, Naples, Italy

Roman CascianoAnalytica International, 24 West 40th Street, NY 10018, USA+1 212 686 4100; +1 212 686 8601; [email protected]

Elisabetta MalangoneAnalytica International, 24 West 40th Street, NY 10018, USA+1 212 686 4100; +1 212 686 8601; [email protected]

Carlo BuonerbaUniversity Federico II of Napoli, Department of Medical Oncology, Endocrinology and Oncology, Naples, Italy

Steven ShermanAnalytica International, 24 West 40th Street, NY 10018, USA+1 212 686 4100; +1 212 686 8601; [email protected]

Jacob WilletAnalytica International, 24 West 40th Street, NY 10018, USA+1 212 686 4100; +1 212 686 8601; [email protected]

Xufang Wang Novartis Pharmaceuticals Corp., East Hanover, NJ, USA

Zhimei Liu Novartis Pharmaceuticals Corp., East Hanover, NJ, USA

Sabino De PlacidoUniversity Federico II of Napoli, Department of Medical Oncology, Endocrinology and Oncology, Naples, Italy

show all

Bibliography

Di Lorenzo G, Casciano R, Malangone E, An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. Expert Opin Pharmacother 2011;12(10):1491-7
PubMed Web of Science ®Google Scholar
Motzer RJ, Escudier B, Oudard S, Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372(9637):449-56
PubMed Web of Science ®Google Scholar
Di Lorenzo G, Carteni G, Autorino R, Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol 2009;27(27):4469-74
PubMed Web of Science ®Google Scholar
Signorovitch JE, Wu EQ, Yu AP, Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics 2010;28(10):935-45
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Authors reply: an adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Authors reply: an adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date